second quarter 2026
Filed Aug 3, 2026Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights
Total net revenue was flat year over year while operating expense categories and net loss increased, but the company reported $598.6 million of cash and cash equivalents and described an FDA-aligned plan to submit the AXPAXLI wet AMD NDA in Q4 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total net revenueother | $13.5 million | – | flat as compared to the comparable quarter of 2025 |
| Gross DEXTENZA product revenue increaseother | $0.1 million | – | 0.6% |
| Collaboration revenueother | $0.0 million | – | – |
| Research and development expensesother | $54.1 million | – | – |
| Selling and marketing expensesother | $17.3 million | – | – |
| General and administrative expensesother | $22.2 million | – | – |
| Net lossother | $(78.8) million | – | – |
| Net loss per share, basic and dilutedother | $(0.35) per share | – | – |
| Outstanding sharesother | approximately 225.0 million | – | – |
Q4 2026 and beyond outlook
- NoteNew Drug Application (NDA) submission for AXPAXLI in wet AMD planned for Q4 2026.
- NoteA pre-NDA meeting with the FDA is scheduled for the third quarter of 2026.
- NoteTopline SOL-R results are now expected in the first quarter of 2028.
- NoteThe Company believes that its current cash balance is sufficient to support its planned operating expenses, debt service obligations, and capital expenditure requirements into 2028.
- NoteThe cash projection does not currently include the full expenses the Company anticipates it needs to support the near-term commercialization of AXPAXLI, if approved.
- NoteCommercial readiness activities are advancing ahead of a potential 2027 launch of AXPAXLI, if approved.
What drove it
- Gross DEXTENZA product revenue, net of discounts, rebates, and returns, increased $0.1 million or 0.6% over Q2 2025.
- Research and development expenses reflected increased overall clinical expenses associated with the ongoing SOL-1, SOL-R, SOL-X and HELIOS-3 clinical trials, additional personnel and professional services, and preparations to submit the planned NDA for AXPAXLI in wet AMD.
- Selling and marketing expense reflected increased personnel-related costs, including stock-based compensation expense, related to commercial-team expansion and pre-commercial investments for a potential AXPAXLI launch.
- General and administrative expense reflected increased personnel-related costs, including stock-based compensation expense, professional fees and facility-related costs.
- FDA Type C meeting minutes formalized SOL-1 trial results with confirmatory evidence as sufficient to support submission of the AXPAXLI NDA in wet AMD.
- The company plans to submit the AXPAXLI NDA under the Section 505(b)(2) pathway, which could accelerate the review timeline by up to 60 days.
- A post-hoc SOL-1 analysis estimated a treatment-burden reduction of up to 72% over 60 weeks with AXPAXLI relative to a projected on-label dosing regimen of aflibercept (2 mg) every 8 weeks.
Concerns
- Total net revenue was flat as compared to the comparable quarter of 2025.
- Net loss increased to $(78.8) million from $(67.8) million for the comparable quarter of 2025.
- SOL-R topline results are now expected in the first quarter of 2028.
- The cash projection does not currently include the full expenses anticipated to support the near-term commercialization of AXPAXLI, if approved.
- AXPAXLI is investigational, and the potential 2027 launch is contingent on approval.
What to watch
- Pre-NDA meeting with the FDA scheduled for the third quarter of 2026.
- Interim SOL-R safety analysis of patients who have reached Week 52 to be conducted in the fourth quarter of 2026.
- Planned Q4 2026 NDA submission for AXPAXLI in wet AMD.
- SOL-R primary endpoint of non-inferiority of AXPAXLI to aflibercept (2 mg) at Week 56.
- SOL-R new key secondary endpoint of superiority to aflibercept (8 mg) at Week 96 and secondary endpoint evaluating prevention of fibrosis and atrophy relative to aflibercept (2 mg) at Week 96.
- HELIOS-3 evaluation of AXPAXLI dosed every 12 months (Q48W) versus sham.
Balance sheet and cash flow
- Total cash and cash equivalents were $598.6 million as of June 30, 2026.
- The Company believes that its current cash balance is sufficient to support its planned operating expenses, debt service obligations, and capital expenditure requirements into 2028.
- The cash projection factors in the completion of the SOL-1 trial and the continued execution of the SOL-R, the SOL-X and the HELIOS-3 trials.
- The projection includes investment in pre-commercial activities and preparations for the potential FDA approval and initial launch of AXPAXLI, but does not currently include the full expenses the Company anticipates it needs to support the near-term commercialization of AXPAXLI, if approved.
Analysis
Ocular reported total net revenue of $13.5 million for the second quarter of 2026, flat as compared to the comparable quarter of 2025. Gross DEXTENZA product revenue increased $0.1 million or 0.6% over Q2 2025, while collaboration revenue was $0.0 million in Q2 2026 versus $0.1 million in Q2 2025. The filing therefore shows a stable commercial revenue base while the company focuses resources on AXPAXLI development and launch preparation.
Operating costs increased across each disclosed category. Research and development expenses were $54.1 million versus $51.1 million, driven by clinical activity across SOL-1, SOL-R, SOL-X and HELIOS-3, as well as personnel, professional services and NDA preparation. Selling and marketing expenses were $17.3 million versus $13.7 million amid commercial-team expansion and pre-commercial investment. General and administrative expenses were $22.2 million versus $14.3 million due to personnel-related costs, stock-based compensation expense, professional fees and facility-related costs.
Net loss was $(78.8) million, compared with $(67.8) million in the comparable 2025 quarter. Net loss per share was $(0.35) per share on both a basic and diluted basis, compared with $(0.39) per share. The per-share comparison reflects the reported outstanding-share count of approximately 225.0 million as of July 31, 2026, while the filing does not provide a direct explanation for the per-share movement.
The key strategic development is the planned Q4 2026 AXPAXLI NDA submission for wet AMD following the May 2026 FDA Type C meeting. The company states that the filing will rely on SOL-1 Week 52 efficacy and safety data, interim SOL-R safety data and confirmatory evidence, and that it intends to use the Section 505(b)(2) pathway. Management also amended SOL-R to add Week 96 secondary assessments, resulting in expected topline SOL-R results in the first quarter of 2028, while stating that SOL-R efficacy data is not required for the NDA submission.
Liquidity supports the stated development plan, with total cash and cash equivalents of $598.6 million as of June 30, 2026 and an expected runway into 2028. This projection includes the listed trials and pre-commercial preparation but excludes the full expenses anticipated for near-term commercialization of AXPAXLI, if approved. The central execution points are the third-quarter pre-NDA meeting, the fourth-quarter interim SOL-R safety analysis and planned NDA submission, and the extent to which future commercial investment expands ahead of a potential 2027 launch.
Management, verbatim
We continue to execute with discipline, precision, and urgency to redefine the retina experience and make AXPAXLI available to patients as early as possible. Our June Investor Day marked a pivotal milestone with the announcement of a clear, FDA-aligned path to submit the AXPAXLI NDA for wet AMD in the fourth quarter of 2026.
Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix
SOL-1 is the first and only successful superiority trial of a novel agent against an approved anti-VEGF therapy since the class emerged two decades ago.
Peter K. Kaiser, MD, Chief Development Officer of Ocular Therapeutix
Not in the filing
stated, not guessed- GAAP or non-GAAP basis was not explicitly identified for the disclosed financial results.
- Prior-year total net revenue amount was not printed on the total net revenue line.
- Prior-quarter comparisons for revenue, expenses, net loss and net loss per share were not provided.
- Gross profit, gross margin and cost of revenue were not provided.
- Operating income or loss was not provided.
- Cash flow from operations and free cash flow were not provided.
- Debt balance and debt-service amount were not provided.
- Share repurchases and dividends were not provided.
- Revenue by reportable operating segment was not provided.
- Financial revenue, gross-margin, operating-expense or tax-rate guidance was not provided.
- No previous outlook section was provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.